Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
Want to see IN:GLENMARK full AI Analyst Report?
GLENMARK Stock Chart & Stats
₹2065.95
-₹29.45(-1.81%)
At close: 4:00 PM EST
₹2065.95
-₹29.45(-1.81%)
Day’s Range― - ―
52-Week Range₹1,605.50 - ₹2,471.05
Previous CloseN/A
Volume301.32K
Average Volume (3M)28.97K
Market Cap
₹605.14B
Enterprise Value₹627.75B
Total Cash (Recent Filing)₹29.58B
Total Debt (Recent Filing)₹12.24B
Price to Earnings (P/E)44.4
Beta0.60
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)35.78
Shares Outstanding282,200,800
10 Day Avg. Volume44,119
30 Day Avg. Volume28,971
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)5.72
Price to Sales (P/S)3.54
P/FCF Ratio30.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)84.62
Revenue Forecast (FY)₹166.82B
Bulls Say, Bears Say
Bulls Say
De-risked Balance SheetA materially lower debt-to-equity (~0.06 in FY2026) meaningfully reduces financial risk and interest burden, increasing flexibility to fund R&D, capex or M&A from internal resources. This durability improves solvency through industry cycles and supports strategic choices.
Margin RecoveryRestored operating (~23.5%) and net (~8.0%) margins after prior losses indicate improved pricing, product mix or cost control. Sustained margins provide internal cash flow for reinvestment and buffer against pricing pressure, enhancing long-term profitability sustainability.
Steady Revenue Growth And Diversified ModelConsistent top-line growth and a business spanning formulations and APIs across geographies create diversified revenue streams and scale economics. This breadth reduces dependence on any single market or product and supports durable commercial resilience and R&D payback.
Bears Say
Inconsistent Cash GenerationVolatile operating and free cash flows — including negative OCF/FCF in FY2024–FY2025 and a FY2026 FCF decline — weaken the company’s ability to reliably fund capex, dividends or bolt-on deals. Persistent inconsistency raises refinancing and operational risk.
Earnings VolatilityLarge swings in profitability reduce earnings visibility and undermine predictable returns on capital. Such volatility complicates long-term planning, investor confidence, and incentives, and suggests exposure to episodic write-downs, one-offs, or business-cycle swings.
Exposure To Pricing/regulatory DynamicsDependence on pricing, reimbursement and regulatory approvals is a structural risk for generics and specialty pharma. Persistent pricing pressure or regulatory delays can compress margins and postpone launches, limiting durable revenue and margin expansion.
Glenmark Pharmaceuticals Limited News
GLENMARK FAQ
What was Glenmark Pharmaceuticals Limited’s price range in the past 12 months?
Glenmark Pharmaceuticals Limited lowest stock price was ₹1605.50 and its highest was ₹2471.05 in the past 12 months.
What is Glenmark Pharmaceuticals Limited’s market cap?
Glenmark Pharmaceuticals Limited’s market cap is ₹605.14B.
When is Glenmark Pharmaceuticals Limited’s upcoming earnings report date?
Glenmark Pharmaceuticals Limited’s upcoming earnings report date is Aug 07, 2026 which is in 56 days.
How were Glenmark Pharmaceuticals Limited’s earnings last quarter?
Glenmark Pharmaceuticals Limited released its earnings results on May 29, 2026. The company reported ₹10.68 earnings per share for the quarter, missing the consensus estimate of ₹18.2 by -₹7.52.
Is Glenmark Pharmaceuticals Limited overvalued?
According to Wall Street analysts Glenmark Pharmaceuticals Limited’s price is currently Overvalued.
Does Glenmark Pharmaceuticals Limited pay dividends?
Glenmark Pharmaceuticals Limited pays a Monthly dividend of ₹2.5 which represents an annual dividend yield of 0.24%. See more information on Glenmark Pharmaceuticals Limited dividends here
What is Glenmark Pharmaceuticals Limited’s EPS estimate?
Glenmark Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Glenmark Pharmaceuticals Limited have?
Glenmark Pharmaceuticals Limited has 282,200,800 shares outstanding.
What happened to Glenmark Pharmaceuticals Limited’s price movement after its last earnings report?
Glenmark Pharmaceuticals Limited reported an EPS of ₹10.68 in its last earnings report, missing expectations of ₹18.2. Following the earnings report the stock price went down -4.55%.
Which hedge fund is a major shareholder of Glenmark Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLENMARK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
Biocon Limited
―
GlaxoSmithKline Pharmaceuticals Limited
―
Lupin Limited
―